Moving the motivation meter

November 8, 2018 by Kim Krieger, University of Connecticut
Two brain cells (pale yellow) and the open space between them, called a synapse. The little blue circles are dopamine, a chemical that excites brain cells when it fills the synapse. Some drugs block the supply of dopamine to the synapse (the red X) and this can cause fatigue, lack of motivation and apathy. The blue X shows where other drugs block a protein from cleaning dopamine out of the synapse; this can help restore feelings of motivation to a person. Or a rat. Credit: John Salamone/UConn)

Two novel drugs kickstart motivation in rats suffering from apathy and a lack of oomph, UConn researchers reported at the Society for Neuroscience conference in San Diego on Nov. 5.

Apathy steals the excitement from life. It's a feeling of being fatigued, uninterested, and emotionally flat. People who suffer from apathy find it hard to exert effort, and life can seem tremendously difficult. One of the primary symptoms of depression, it's also a side effect of certain medications. It can also be caused by inflammation from an infection or chronic disease such as multiple sclerosis.

Apathy and lack of are hard to treat. Many medications that help with other symptoms of depression don't help much with them.

But now, UConn behavioral neuroscientist John Salamone and graduate student Renee Rotolo have found that two can restore normal behavior in rats who lack motivation, pointing the way to potential treatments.

Salamone and Rotolo's rats were not naturally lacking motivation; the researchers induced it with a that reduces signals in the brain. Dopamine affects many things, including mood, motivation, and movement. It works by affecting brain cells when it is released into the synapses (the spaces between the cells). Certain medicines used to treat movement disorders restrict the amount of dopamine available to fill the synapses in the brain. This does calm spastic movements, but it can also cause apathy, fatigue, and low exertion of effort.

Salamone, Rotolo, and other lab members showed that rats given the drug that reduced dopamine were much less likely to work for preferred morsels of food. But when these were then given one of the experimental drugs, they regained their motivation to work for the treat.

Both of the experimental drugs Rotolo and Salamone tested stimulate a build up of dopamine in the synapse. They do this by inhibiting the protein that normally clears dopamine away. Other drugs, such as cocaine and amphetamines, work in a similar fashion, but their onset is much faster and the effects more extreme.

"You wouldn't want to give a person with depression cocaine over and over again. They'd crash. These [experimental] drugs provide a long, slow, mild increase in dopamine," which would be much more likely to be therapeutic, Salamone says. They also, hopefully, may have a lower potential for abuse.

One of the new drugs was developed by the British pharmaceutical company Chronos Therapeutics; the other by an Austrian medicinal chemist Gert Lubec from the Universities of Vienna and Salzburg. Lubec has developed a large family of related drug candidates to increase motivation, all related to modafinil. Modafinil, a drug developed initially to enhance wakefulness, also helps people concentrate on a task and engage with it more. Neuroscientists believe it does this by blocking the inactivation of dopamine from synapses in the brain responsible for attention and focus. Lubec intentionally changed the chemical structure of the drug, which made it even more selective for actions on dopamine.

The next step in the research will be to test these other, related drugs in the series and see if they have similar effects, and identify which one works best to mitigate and fatigue. Salamone's team also intends to test whether the compounds really do have less potential for abuse than more rapidly acting drugs.

Explore further: Dopamine not about pleasure (anymore)

Related Stories

Dopamine not about pleasure (anymore)

December 3, 2012
(Medical Xpress)—To John Salamone, professor of psychology and longtime researcher of the brain chemical dopamine, scientific research can be very slow-moving.

Dopamine receptor study offers hope for improved treatments with fewer side effects

September 4, 2018
New work from researchers at Columbia University Vagelos College of Physicians and Surgeons sheds light on how dopamine receptors signal within cells, opening the door for more targeted—and more tolerable—therapeutics ...

Dopamine regulates the motivation to act

April 29, 2013
The widespread belief that dopamine regulates pleasure could go down in history with the latest research results on the role of this neurotransmitter. Researchers have proved that it regulates motivation, causing individuals ...

New theory integrates dopamine's role in learning, motivation

November 24, 2015
If you've ever felt lackadaisical to start a new project, focus on imagining the joy of completing it, say University of Michigan researchers.

Dopamine, drugs, and depression

February 1, 2018
The neurotransmitter dopamine plays a major role in mental illnesses like substance abuse disorders and depressive disorders, as well as a more general role in reward and motivational systems of the brain. But there are still ...

New optical probes allow ultrafast imaging of dopamine activity in the brain

June 4, 2018
UC Davis neuroscientist Lin Tian and her team, Tommaso Patriarchi, Gerard Broussard and Ruqiang Liang, have developed fluorescence sensors that are opening a new era for the optical recording of dopamine activity in the living ...

Recommended for you

What prevents remyelination? New stem cell research reveals a critical culprit

December 18, 2018
New research on remyelination, the spontaneous regeneration of the brain's fatty insulator that keeps neurons communicating, could lead to a novel approach to developing treatments for multiple sclerosis (MS) and other inflammatory ...

Genetic changes tied to rare brain bleeds in babies

December 18, 2018
(HealthDay)—Researchers say they've identified genetic mutations linked with a blood vessel defect that can lead to deadly brain bleeds in babies.

Gene variant found in brain complicit in MS onset

December 18, 2018
Multiple sclerosis (MS) is an autoimmune disease affecting the function of the central nervous system. Up to now, most of the 230 genetic variants associated with the disease have been linked to changes in immune cells. However, ...

Biologists identify promising drug for ALS treatment

December 18, 2018
A drug typically used to treat hepatitis could slow the progression of ALS, also known as Lou Gehrig's disease, according to new research by University of Alberta scientists.

Communication between neural networks

December 18, 2018
The brain is organized into a super-network of specialized networks of nerve cells. For such a brain architecture to function, these specialized networks – each located in a different brain area – need to be able to communicate ...

Neurons with good housekeeping are protected from Alzheimer's

December 17, 2018
Some neurons in the brain protect themselves from Alzheimer's with a cellular cleaning system that sweeps away toxic proteins associated with the disease, according to a new study from Columbia University and the University ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Anonym518498
1 / 5 (1) Nov 08, 2018
you can never be taking too many drugs
SciTechdude
not rated yet Dec 07, 2018
Tell that to your next cup of coffee.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.